Dysferlinopathy Fibroblasts Are Defective in Plasma Membrane Repair

PLoS Curr. 2015 Oct 29:7:ecurrents.md.5865add2d766f39a0e0411d38a7ba09c. doi: 10.1371/currents.md.5865add2d766f39a0e0411d38a7ba09c.

Abstract

Background: Dysferlin is a sarcolemmal protein that is defective in Miyoshi myopathy and limb-girdle muscular dystrophy type 2B, and is involved in sarcolemmal repair. Primary cultured myoblasts and myotubes established from patient muscle biopsies have been widely utilized to explore the molecular mechanism of dysferlinopathy.

Objectives: The purpose of this study was to explore the possible utility of dermal fibroblasts from dysferlin-deficient patients and SJL mice as a tool for studying dysferlinopathy.

Methods: Dysferlin protein expression in fibroblasts from dysferlin-deficient patients and SJL mice was analyzed by immunoblotting and immunocytochemistry. The membrane wound-repair assay was performed on the fibroblasts using a confocal microscope equipped with a UV-laser. The membrane blebbing assay using hypotonic shock, in which normal membrane blebbing is detected only in the presence of dysferlin, was also performed using human and mouse fibroblasts.

Results: Mis-sense mutated dysferlin was expressed at a very low level in fibroblasts from a dysferlinopathy patient, and lower expression level of truncated dysferlin was observed in SJL mouse fibroblast. Fibroblasts from patients with dysferlinopathy and SJL mice showed attenuated membrane repair and did not form membrane blebs in response to hypoosmotic shock. Proteosomal inhibitior increased mis-sense mutated or truncated dysferlin levels, and restored membrane blebbing, however, proteosomal inhibition failed to improve levels of dysferlin with non-sense or frame-shift mutation.

Conclusion: Fibroblasts from dysferlinopathy patients and SJL mice showed attenuated plasma membrane repair, and could be a tool for studying dysferlinopathy.

Grants and funding

This study was partly supported by an intramural Research Grant 23-4 (to YKH), 23-5 (to CM, IN) and 26-8 (IN) for Neurological and Psychiatric Disorders from NCNP; a grant for Research on Intractable Diseases, Comprehensive Research on Disability Health and Welfare (to YKH, IN), and Applying Health Technology (to IN) from the Ministry of Health, Labour and Welfare; and JSPS KAKENHI Grant Numbers 24390227 (to YKH) and 24659437 (to YKH)